Photobiomodulation, or PBM, uses low-level red and near-infrared light to influence cellular energy production. In ophthalmology, it's being studied most seriously for retinal conditions like dry age-related macular degeneration, where mitochondrial stress in the retina and RPE plays a central role. In this episode, Dr. Saikumar Gandapodi walks through the biology — how light interacts with cytochrome c oxidase, why the retina is uniquely metabolically demanding, and what recent human trials do and don't tell us.

We separate the established from the emerging at every turn. Dr. Gandapodi is candid about the limits: PBM is not a cure, dosing is still being worked out, and much of the mechanistic story comes from lab and animal models. He also explains how PBM fits into an integrative, whole-person framework at Netra Eye Institute — always as an adjunct to standard ophthalmic care, never a replacement.

This is a research-driven conversation for anyone curious about where light-based therapy is genuinely heading in eye medicine, and how to think critically about early but promising science.

Where systems biology, root-cause thinking, and standard eye care meet.

What does it actually mean to practice integrative ophthalmology, and how is it different from the eye care most patients already know? In this episode, Dr. Saikumar Gandapodi, Board-Certified Doctor of Oriental Medicine, Ayurvedic practitioner, and Founder of Netra Eye Institute, sits down to define an emerging clinical discipline that treats the eye as part of the whole body rather than an isolated organ.

We explore where conventional ophthalmology excels, where chronic eye disease leaves gaps, and how concepts like ocular blood flow, oxidative stress, inflammation, and the gut-eye axis are being studied as contributors to disease. Dr. Gandapodi explains Netra Restoration Therapy as a multi-target, adjunctive approach, and he is candid throughout about what is established versus what remains early and hypothesis-generating.

This is a research-driven conversation for an educated audience curious about the future of eye health, told without hype and without dismissing the surgery and pharmaceuticals that save sight every day.

Age-related macular degeneration is usually described as a problem of aging and drusen. But a growing body of research points to something deeper: a slow failure of energy metabolism in the retina and the cells that support it. In this episode, Dr. Saikumar Gandapodi, Founder and Director of Netra Eye Institute, reframes AMD as a disease of metabolic exhaustion in the retinal pigment epithelium and photoreceptors.

We explore why the macula is metabolically the most demanding tissue in the body, how mitochondrial dysfunction, oxidative stress, and lipid handling failures set the stage for drusen and cell death, and what conventional care does well. Dr. Gandapodi explains the evidence behind anti-VEGF therapy and the AREDS trials, and where meaningful gaps remain.

He also introduces Netra Restoration Therapy, an integrative, adjunct approach aimed at supporting mitochondrial function, oxidative balance, and ocular blood flow. Throughout, the conversation stays honest about what is established, what is emerging, and what remains hypothesis.

Glaucoma is often described as a pressure disease, but at its core it's a disease of dying nerve cells. In this episode, Dr. Saikumar Gandapodi joins us to unpack what neuroprotection really means in glaucoma, why lowering eye pressure remains the foundation of care, and where the gaps in that approach open the door for adjunct strategies.

We explore the biology of retinal ganglion cell loss, the roles of ocular blood flow, mitochondrial function, oxidative stress, and neurotrophin decline, and what the human evidence actually supports versus what remains hypothesis. Dr. Gandapodi also explains how his integrative framework, Netra Restoration Therapy, is intended to complement conventional treatment rather than replace it.

This is a candid, evidence-informed conversation for anyone who wants to understand where glaucoma care is heading and how to think clearly about promise versus proof.

Diabetic retinopathy has long been treated as a disease of leaky, fragile blood vessels, with anti-VEGF injections as a cornerstone of care. But a growing body of research suggests the story starts earlier — in the retina's neurons and glia — well before the classic vascular signs appear. In this episode, Dr. Saikumar Gandapodi joins us to unpack what it means to view diabetic retinopathy as a neurovascular disease.

We explore the unit that links neurons, glia, and vessels, why anti-VEGF therapy is powerful yet incomplete, and where mechanisms like oxidative stress, chronic inflammation, and neurotrophin decline may fit. Dr. Gandapodi explains how the Netra Restoration Therapy framework approaches the eye as part of a whole metabolic system — always as a complement to, never a replacement for, standard ophthalmic care.

Throughout, we stay honest about the evidence: separating what's established from what's still emerging, distinguishing lab and animal work from human trials, and focusing on what patients living with diabetes can actually take away today.

For decades, keratoconus was described as a purely mechanical, non-inflammatory thinning of the cornea. That story is changing. A growing body of research points to enzymatic activity, oxidative stress, and inflammatory mediators in the tears of people with keratoconus, alongside the mechanical instability that corneal cross-linking is designed to halt.

In this episode, host Maya Rao sits down with Dr. Saikumar Gandapodi, Board-Certified Doctor of Oriental Medicine, Ayurvedic practitioner, and Founder of Netra Eye Institute, to explore what the evidence actually supports about the biology of keratoconus. They discuss the enduring value of cross-linking, the role of eye rubbing and the ocular surface, and where integrative, adjunct strategies might complement standard care.

Throughout, the conversation stays grounded: established science is separated from emerging hypotheses, no cures are promised, and integrative approaches are framed only as complements to proven ophthalmic treatment.

Normal-tension glaucoma challenges the old idea that glaucoma is simply a disease of high eye pressure. In this episode, Dr. Saikumar Gandapodi joins us to unpack what the evidence actually shows about optic nerve damage occurring at statistically normal intraocular pressures, and why blood flow, vascular regulation, and systemic factors matter so much here.

We explore Flammer syndrome, a described pattern of vascular dysregulation that shows up in some patients with normal-tension glaucoma, and separate what is established from what is still emerging. Dr. Gandapodi explains how conventional pressure-lowering care remains the proven foundation, and where careful, evidence-informed integrative support may complement it.

This is a research-driven conversation for an educated audience curious about the future of eye care. No cures are promised. Instead, we look honestly at the science of neuroprotection, ocular perfusion, and whole-person care around a condition that still keeps clinicians humble.

Glaucoma has long been defined by intraocular pressure — but a growing body of research shows that many patients continue to lose vision even when their pressure is beautifully controlled. Why? In this episode, host Priya Menon sits down with Dr. Saikumar Gandapodi, Board-Certified Doctor of Oriental Medicine, practitioner of Ayurvedic Medicine, and Founder and Director of Netra Eye Institute, to explore one of the most compelling frontiers in modern eye care: ocular blood flow and vascular dysregulation.

Together they unpack the science of optic nerve perfusion, endothelial dysfunction, Flammer Syndrome, oxidative stress, mitochondrial fragility, and the neurotrophic decline that leaves retinal ganglion cells vulnerable. Dr. Gandapodi translates concepts from vascular biology, functional medicine, and network pharmacology into an accessible framework — explaining where conventional, pressure-focused management is powerful, where it can fall short, and where adjunct, systems-based strategies may add value.

This is not a conversation about replacing surgery or medication. It is an evidence-informed exploration of the broader biological environment surrounding the optic nerve — from the gut-eye axis to Ginkgo biloba trials — and how Netra Restoration Therapy approaches glaucoma as a multifactorial, whole-person condition. Balanced, rigorous, and forward-looking, this episode is essential listening for patients and clinicians alike.